<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03026257</url>
  </required_header>
  <id_info>
    <org_study_id>LCW773-P001</org_study_id>
    <nct_id>NCT03026257</nct_id>
  </id_info>
  <brief_title>Clinical Assessment of a HYDRAGLYDE® Regimen</brief_title>
  <official_title>Clinical Assessment of a Regimen of AIR OPTIX® Plus HYDRAGLYDE® Silicone Hydrogel Lenses and HYDRAGLYDE® Containing Lens Care Solutions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon, a Novartis Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate worn AIR OPTIX® plus HYDRAGLYDE® (AOHG) lenses
      cleaned and disinfected with HYDRAGLYDE® containing lens solutions compared to each of the
      control habitual silicone hydrogel (SiHy) lenses cleaned and disinfected with habitual
      multi-purpose solution (MPS) for cholesterol uptake.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 13, 2017</start_date>
  <completion_date type="Actual">August 18, 2017</completion_date>
  <primary_completion_date type="Actual">August 18, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ex vivo total cholesterol uptake at Day 30</measure>
    <time_frame>Day 30</time_frame>
    <description>Cholesterol deposits will be assessed on worn right (OD) contact lenses. Lower deposits indicate increased lens performance.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">323</enrollment>
  <condition>Refractive Errors</condition>
  <condition>Myopia</condition>
  <condition>Hypermetropia</condition>
  <arm_group>
    <arm_group_label>AOHG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lotrafilcon B contact lenses with added wetting agent, worn bilaterally (in both eyes) for 30 days in a daily wear modality and cared for with either a hydrogen peroxide-based contact lens solution with added wetting agent or a POLYQUAD/ALDOX-preserved contact lens solution with added wetting agent, as randomized</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Habitual</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Habitual silicone hydrogel contact lenses worn bilaterally for 30 days in a daily wear modality and cared for with participant's habitual multi-purpose solution (MPS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lotrafilcon B contact lenses with added wetting agent</intervention_name>
    <description>Silicone hydrogel contact lenses</description>
    <arm_group_label>AOHG</arm_group_label>
    <other_name>AIR OPTIX® plus HYDRAGLYDE® (AOHG)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Samfilcon A contact lenses</intervention_name>
    <description>Habitual silicone hydrogel contact lenses</description>
    <arm_group_label>Habitual</arm_group_label>
    <other_name>Bausch + Lomb ULTRA™ (Ultra)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>POLYQUAD/ALDOX-preserved contact lens solution with added wetting agent</intervention_name>
    <description>Multi-purpose disinfecting solution for contact lens care</description>
    <arm_group_label>AOHG</arm_group_label>
    <other_name>OPTI-FREE® PureMoist® (OFPM)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hydrogen peroxide-based contact lens solution with added wetting agent</intervention_name>
    <description>Solution for contact lens cleaning and disinfecting</description>
    <arm_group_label>AOHG</arm_group_label>
    <other_name>CLEAR CARE® PLUS/AOSEPT® PLUS with HYDRAGLYDE® (CCP)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Senofilcon C contact lenses</intervention_name>
    <description>Habitual silicone hydrogel contact lenses</description>
    <arm_group_label>Habitual</arm_group_label>
    <other_name>Johnson &amp; Johnson ACUVUE® VITA™ (Vita)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Senofilcon A contact lenses</intervention_name>
    <description>Habitual silicone hydrogel contact lenses</description>
    <arm_group_label>Habitual</arm_group_label>
    <other_name>Johnson &amp; Johnson ACUVUE® OASYS® 2- Week with HYDRACLEAR® PLUS (Oasys)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Comfilcon A contact lenses</intervention_name>
    <description>Habitual silicone hydrogel contact lenses</description>
    <arm_group_label>Habitual</arm_group_label>
    <other_name>CooperVision® Biofinity® (Biofinity)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Habitual Multi-Purpose Solution (HMPS)</intervention_name>
    <description>Multi-purpose solution for contact lens care according to participant's habitual brand, used per manufacturer's instructions</description>
    <arm_group_label>Habitual</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must sign informed consent document;

          -  Vision correctable to 0.1 (LogMAR) or better in each eye at distance with habitual
             lenses;

          -  Manifest cylinder (at screening) less than or equal to 0.75 diopter (D) in each eye
             and spectacle add &lt;+0.50 D in each eye;

          -  Current full-time wearer of spherical samfilcon A, comfilcon A, senofilcon C monthly
             or senofilcon A 2-week replacement lens within the power range of lens powers
             available;

          -  Current user of an MPS (excluding OFPM) to care for lenses;

          -  Willing to answer text messages on a daily basis during the study;

          -  Willing to discontinue artificial tears during the study and rewetting drops on the
             days of study visits;

          -  Use of digital devices (eg, smart phone, tablet, laptop or desktop computer) for 20
             consecutive minutes at least twice a week and willing to continue for the duration of
             the study;

          -  Other protocol specific inclusion criteria may apply.

        Exclusion Criteria:

          -  Habitual lens wear in an extended wear modality (routinely sleeping in lenses
             overnight for 1 or more nights per week);

          -  Any anterior segment infection, inflammation, disease or abnormality that
             contraindicates contact lens wear;

          -  History of herpetic keratitis, corneal surgery or irregular cornea;

          -  Prior refractive surgery;

          -  Any use of systemic or ocular medications for which contact lens wear could be
             contraindicated as determined by the investigator;

          -  Currently using or have not discontinued Restasis®, XiidraTM and/or topical steroids
             within the past 7 days;

          -  Use of mechanical eyelid therapy or eyelid scrubs within 14 days before Visit 1 and
             not willing to discontinue during the study;

          -  Monocular (only 1 eye with functional vision) or fit with only 1 lens;

          -  Known pregnancy or lactating;

          -  Other protocol specific exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Manager, Global Med Affairs, GCRA</last_name>
    <role>Study Director</role>
    <affiliation>Alcon, A Novartis Division</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2L3G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Hildesheim</city>
        <zip>31134</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigative Site</name>
      <address>
        <city>Jena</city>
        <zip>07745</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2017</study_first_submitted>
  <study_first_submitted_qc>January 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2017</study_first_posted>
  <last_update_submitted>August 22, 2017</last_update_submitted>
  <last_update_submitted_qc>August 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Refractive Errors</mesh_term>
    <mesh_term>Hyperopia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Hydrogen Peroxide</mesh_term>
    <mesh_term>Contact Lens Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

